Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.

ABSTRACT:

Background

Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment.

Aims

We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients.

Methods

In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Pa

SUBMITTER: Ter Haar ELM 

PROVIDER: S-EPMC9300332 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature